BioTech Breakthrough Awards Badge[1] copy.jpg
Syncell’s Microscoop Winner of BioTech Breakthrough Award For “Proteomics Solution of the Year”
21 nov. 2024 20h16 HE | BioTech Breakthrough
TAIPEI, Taiwan and WATERTOWN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Syncell, a leader in next-generation subcellular protein purification and spatial proteomics analysis, today announced that...
cmi_logo.png
[Latest] Global Cancer Cell Analysis Market Size/Share Worth USD 23.31 Billion by 2033 at a 8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 nov. 2024 13h00 HE | Custom Market Insights
Austin, TX, USA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Cell Analysis Market Size, Trends and Insights By Application (Cancer...
Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
04 nov. 2024 07h30 HE | Angitia Incorporated Limited
WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
barinthuslogo.jpg
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24 sept. 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Full Logo - OKYO .jpg
OKYO Pharma Announces Chairman Acquires Shares
10 sept. 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
27 août 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
15 août 2024 12h13 HE | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
06 août 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Fellowship Announcement (Instagram Post (Square)) (Facebook Post)
The Foundation for Sarcoidosis Research Awards $300,000 to Support Early-Career Investigators Through the Sarcoidosis Research Fellowship Grant
24 juil. 2024 13h16 HE | Foundation for Sarcoidosis Research
CHICAGO, July 24, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is pleased to announce that Dr. Greer Waldrop, University of California, San Francisco, and Dr. Miles...
Figure 1
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
10 juil. 2024 07h00 HE | OKYO Pharma LTD
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...